Sees FY26 revenue $1.055B-$1.115B, consensus $1.04B. Sees FY26 adjusted EBITDA $275M-$290M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
- ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
- ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
- ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’